A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
That was never funded. Yeah, we discussed it with them, and I actually think a proposal was written, and they were thinking about funding it, and then the program officer left, and the next program officer said they weren't interested in it, and that was the end of it.
-
So then the dengue program, it was under the Pandemic Prevention Path, the platform P3.
-
It's funny around that grant. That grant went to the Pacific Northwest Labs, and then they asked me to participate on dengue virus with it. So I don't know the name of the request.
-
Okay. Have you ever done any work with any laboratories in Sri Lanka?
-
2026-04-10 09:00
Ralph S. Baric
Sri Lanka.
-
Mm-hmm.
-
A good collaborator that I have, who is Aravinda de Silva, who came from Sri Lanka, has connections there. And I've been funded with Aravinda and Eva Harris for a variety of dengue research and Zika research. So serum samples, we've gotten serum samples from both Sri Lanka and from the Philippines and from Nicaragua to do studies on flavivirus evolution, and identifying major DC.Scheduling@LexitasLegal.com neutralizing epitopes for the development of therapeutic antibodies in vaccines. But I have never been to Sri Lanka or the Philippines. I have been to Nicaragua for a meeting with a P01 that I had, and currently have with Eva Harris, that studies dengue virus pathogenesis. It studied dengue virus pathogenesis in children in Nicaragua for the past 20-some years. It's the longest-running natural infection cohort on dengue virus, which has identified a large number of important features associated with what drives pathogenesis, and has informed the vaccine development. Currently we're funded with Aravinda to develop next12 generation protein-designed vaccines against dengue.
-
And what agency funds the work that you had done --
-
NIH.